Dean Capital Investments Management LLC acquired a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,818 shares of the medical research company’s stock, valued at approximately $664,000.
Other large investors also recently added to or reduced their stakes in the company. Baker Ellis Asset Management LLC purchased a new stake in Amgen in the third quarter worth $108,000. Phocas Financial Corp. purchased a new stake in Amgen in the second quarter worth $110,000. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Omnia Family Wealth LLC lifted its stake in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. Finally, Horan Capital Advisors LLC. purchased a new stake in Amgen in the third quarter worth $150,000. 79.61% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the transaction, the executive vice president now directly owns 56,106 shares in the company, valued at $9,921,223.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 4,575 shares of company stock valued at $818,361 over the last 90 days. Corporate insiders own 0.19% of the company’s stock.
Amgen, Inc. (NASDAQ:AMGN) opened at $191.10 on Monday. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $137,699.44, a price-to-earnings ratio of 15.19, a PEG ratio of 2.35 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same quarter in the previous year, the business earned $2.89 earnings per share. Amgen’s revenue was down 2.7% compared to the same quarter last year. sell-side analysts anticipate that Amgen, Inc. will post 13.22 EPS for the current fiscal year.
Amgen announced that its board has approved a stock repurchase program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 2.76%. Amgen’s payout ratio is presently 205.45%.
TRADEMARK VIOLATION NOTICE: “Dean Capital Investments Management LLC Acquires New Position in Amgen, Inc. (AMGN)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3256940/dean-capital-investments-management-llc-acquires-new-position-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.